Document is current
Any future updates will be listed below
-
Authors
Ruan, Dan-Yun
Wu, Hao-Xiang
Luo, Su-Xia
Huang, Wen-Wen
Liang, Xin-Jun
Niu, Zuo-Xing
Dang, Qi
Li, Hong-Li
Pan, Zhan-Yu
Lu, Hong-Xia
Zhang, Yan-Qiao
Li, Xing-Ya
Xiao, Xiu-Ying
Cai, Shi-Rong
Dong, Yu-Gang
Zhang, Jian
Li, Zhou
Lan, Hai-Tao
Wang, Xin
Zhou, Ying
Liu, Lian
Liu, He-Li
Xu, Ping-Sheng
Suo, Ai-Li
Jia, Rui-Nuo
Li, Yong-Qiang
Peng, Xiao-Dong
Wang, Si-Chen
Yu, Ai-Ai
Xie, Jie
Qiu, Miao-Zhen https://orcid.org/0000-0002-4774-6235
Xu, Rui-Hua https://orcid.org/0000-0001-9771-8534
-
Funding
Funding for this research was provided by:
Jiangsu Hengrui Pharmaceuticals
- License Information
-
More Information
Article History
Received: 22 January 2025
Accepted: 19 May 2025
First Online: 16 July 2025
Competing interests
: R.-H.X. has served in a consulting or advisory role for Bristol Myers Squibb, Merck Serono, Roche, Astellas, AstraZeneca, Junshi, Hengrui, BeiGene and CPPC. S.-C.W., A.-A.Y. and J.X. are employed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. The other authors declare no competing interests.
